ArticleArthritis research & therapy2026
MSMP promotes an aberrant phenotype of fibroblast-like synoviocytes in rheumatoid arthritis by blocking autophagy via the RUNX1/GPR137B axis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of YAP/TAZ Mechanobiological Signaling in Osteoporosis and Osteoarthritis.Calcified tissue international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundMicroseminoprotein (MSMP) is a secreted protein that has been identified as a novel ligand for C-C chemokine receptor 2 (CCR2), despite lacking the classical chemokine structure. Emerging evidence suggests that MSMP is implicated in the progression of various cancers and inflammatory diseases. However, its role in rheumatoid arthritis (RA) remains unknown. The study aims to investigate the regulatory mechanism of MSMP in RA.
methodsWe screened MSMP as a candidate gene from the GEO database. RT-qPCR was used to detect mRNA expression, and protein expression was evaluated by Western blotting. The concentrations of MSMP or inflammatory cytokines were examined by ELISA. Cell migration and invasion were assessed with a Transwell system. EdU incorporation assay was used to determine cell proliferation. Cell apoptosis was measured by Annexin V-FITC using flow cytometry. Dual-luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to analyze promoter activity and transcription factor binding, respectively. In vivo experiments were carried out using a collagen-induced arthritis (CIA) model.
resultsMSMP expression was increased in fibroblast-like synoviocytes (FLSs) and synovial tissues (STs) from RA patients. Functional experiments showed that MSMP knockdown inhibited the migration and invasion of RA FLSs. Mechanistically, we identified GPR137B as a downstream target of MSMP. Our results also revealed that the transcription factor RUNX1 controlled GPR137B expression by binding to the promoter region of GPR137B. Furthermore, GPR137B knockdown reduced the migration and invasion of RA FLSs by promoting autophagy, and these effects were partially reversed by treatment with the autophagy inhibitor 3-Methyladenine (3-MA). Intriguingly, intra-articular Ad-shRNA-MSMP administration alleviated the severity of arthritis in mice with CIA.
conclusionOur results suggest that elevated MSMP levels in FLSs may contribute to rheumatoid synovial aggression and joint destruction by suppressing autophagy via the RUNX1/GPR137B axis. MSMP may be a potential target against RA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.